CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Biodesix, Inc. - BDSX CFD

1.9768
3.12%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0564
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.9169
Open* 1.9269
1-Year Change* -47.78%
Day's Range* 1.9269 - 1.9968
52 wk Range 0.96-4.04
Average Volume (10 days) 139.05K
Average Volume (3 months) 4.06M
Market Cap 138.35M
P/E Ratio -100.00K
Shares Outstanding 71.69M
Revenue 35.83M
EPS -1.73
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 6, 2023 1.9768 0.0499 2.59% 1.9269 2.0168 1.9269
Feb 3, 2023 1.9169 -0.1498 -7.25% 2.0667 2.1067 1.7871
Feb 2, 2023 2.1466 -0.2296 -9.66% 2.3762 2.4262 2.1266
Feb 1, 2023 2.3263 -0.1099 -4.51% 2.4362 2.4362 2.2663
Jan 31, 2023 2.3862 -0.0399 -1.64% 2.4261 2.5061 2.3262
Jan 30, 2023 2.3862 -0.0299 -1.24% 2.4161 2.4561 2.2663
Jan 27, 2023 2.4661 0.1598 6.93% 2.3063 2.4961 2.2963
Jan 26, 2023 2.3163 -0.0200 -0.86% 2.3363 2.4961 2.2763
Jan 25, 2023 2.3563 -0.0399 -1.67% 2.3962 2.4561 2.2663
Jan 24, 2023 2.3463 0.0200 0.86% 2.3263 2.3962 2.3063
Jan 23, 2023 2.3263 0.0100 0.43% 2.3163 2.3962 2.2264
Jan 20, 2023 2.3862 0.1498 6.70% 2.2364 2.3862 2.1965
Jan 19, 2023 2.2165 -0.0199 -0.89% 2.2364 2.2365 2.1765
Jan 18, 2023 2.2464 -0.1697 -7.02% 2.4161 2.4162 2.1665
Jan 17, 2023 2.3862 -0.0799 -3.24% 2.4661 2.4861 2.3462
Jan 13, 2023 2.4761 0.1498 6.44% 2.3263 2.4861 2.2464
Jan 12, 2023 2.4661 0.0599 2.49% 2.4062 2.4661 2.3262
Jan 11, 2023 2.3862 -0.0100 -0.42% 2.3962 2.4561 2.2464
Jan 10, 2023 2.3563 -0.0599 -2.48% 2.4162 2.4162 2.1466
Jan 9, 2023 2.3463 0.1698 7.80% 2.1765 2.3862 2.1665

Biodesix, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2018 2019 2020 2021
Total revenue 20.432 24.552 45.557 54.506
Revenue 20.432 24.552 45.557 54.506
Cost of Revenue, Total 4.406 6.074 21.998 30.518
Gross Profit 16.026 18.478 23.559 23.988
Total Operating Expense 44.095 51.293 68.491 93.148
Selling/General/Admin. Expenses, Total 25.899 30.637 32.328 47.958
Research & Development 8.188 10.468 10.818 12.789
Unusual Expense (Income) 5.602 4.114 0.818 -0.676
Operating Income -23.663 -26.741 -22.934 -38.642
Interest Income (Expense), Net Non-Operating -2.892 -2.953 -7.586 -4.508
Other, Net 0.389 -1.032 -0.83 -0.009
Net Income Before Taxes -26.166 -30.726 -31.35 -43.159
Net Income After Taxes -26.166 -30.726 -31.35 -43.159
Net Income Before Extra. Items -26.166 -30.726 -31.35 -43.159
Net Income -26.166 -30.726 -31.35 -43.159
Income Available to Common Excl. Extra. Items -26.166 -30.726 -31.35 -43.159
Income Available to Common Incl. Extra. Items -26.166 -30.726 -31.35 -43.159
Diluted Net Income -26.166 -30.726 -31.35 -43.159
Diluted Weighted Average Shares 26.2541 26.2541 26.5615 27.365
Diluted EPS Excluding Extraordinary Items -0.99665 -1.17033 -1.18028 -1.57716
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.78327 -1.01363 -1.14948 -1.60186
Depreciation / Amortization 2.529 2.559
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 28.866 11.885 6.531 7.224 6.548
Revenue 28.866 11.885 6.531 7.224 6.548
Cost of Revenue, Total 18.218 7.085 2.722 2.493 3.235
Gross Profit 10.648 4.8 3.809 4.731 3.313
Total Operating Expense 35.177 22.472 16.499 19 21.009
Selling/General/Admin. Expenses, Total 11.927 11.425 13.607 13.558 14.487
Research & Development 3.321 3.323 3.293 2.852 3.206
Unusual Expense (Income) 1.711 0.639 -3.123 0.097 0.081
Operating Income -6.311 -10.587 -9.968 -11.776 -14.461
Interest Income (Expense), Net Non-Operating -0.651 -0.815 -1.546 -1.496 -1.137
Other, Net 0.001 0 0 -0.01 0.012
Net Income Before Taxes -6.961 -11.402 -11.514 -13.282 -15.586
Net Income After Taxes -6.961 -11.402 -11.514 -13.282 -15.586
Net Income Before Extra. Items -6.961 -11.402 -11.514 -13.282 -15.586
Net Income -6.961 -11.402 -11.514 -13.282 -15.586
Income Available to Common Excl. Extra. Items -6.961 -11.402 -11.514 -13.282 -15.586
Income Available to Common Incl. Extra. Items -6.961 -11.402 -11.514 -13.282 -15.586
Diluted Net Income -6.961 -11.402 -11.514 -13.282 -15.586
Diluted Weighted Average Shares 26.604 27.73 28.051 27.059 31.07
Diluted EPS Excluding Extraordinary Items -0.26165 -0.41118 -0.41047 -0.49085 -0.50164
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.19734 -0.38814 -0.5218 -0.48727 -0.49903
  • Annual
  • Quarterly
2018 2019 2020 2021
Total Current Assets 9.913 12.7 86.14 43.613
Cash and Short Term Investments 5.914 5.286 62.126 32.712
Cash & Equivalents 5.914 5.286 62.126 32.712
Total Receivables, Net 1.892 5.292 15.304 3.656
Accounts Receivable - Trade, Net 1.892 5.292 15.304 3.656
Other Current Assets, Total 2.107 2.122 8.71 7.245
Total Assets 39.057 41.633 121.07 76.097
Property/Plant/Equipment, Total - Net 1.388 2.12 3.178 4.179
Property/Plant/Equipment, Total - Gross 6.956 8.506 9.902 10.928
Accumulated Depreciation, Total -5.568 -6.386 -6.724 -6.749
Goodwill, Net 10.804 11.631 15.031 15.031
Intangibles, Net 16.852 15.092 13.26 11.617
Other Long Term Assets, Total 0.1 0.09 3.461 1.657
Total Current Liabilities 4.468 22.6 32.125 28.96
Accounts Payable 0.886 1.717 8.964 1.662
Accrued Expenses 1.568 1.899 4.69 4.899
Notes Payable/Short Term Debt 0 12.045 0 0
Other Current Liabilities, Total 2.014 6.939 6.631 22.38
Total Liabilities 53.125 76.213 79.904 56.37
Total Long Term Debt 23.099 23.812 15.926 9.993
Long Term Debt 23.099 23.812 15.926 9.993
Other Liabilities, Total 25.558 29.801 31.853 17.417
Total Equity -14.068 -34.58 41.166 19.727
Redeemable Preferred Stock 183.962 193.959 0 0
Common Stock 0.001 0.001 0.027 0.031
Additional Paid-In Capital 2.107 2.324 299.953 321.669
Retained Earnings (Accumulated Deficit) -200.138 -230.864 -258.814 -301.973
Total Liabilities & Shareholders’ Equity 39.057 41.633 121.07 76.097
Total Common Shares Outstanding 26.2541 26.2541 26.5615 30.7896
Current Port. of LT Debt/Capital Leases 0 11.84 0.019
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 81.244 68.45 56.445 43.613 27.233
Cash and Short Term Investments 55.329 56.349 47.913 32.712 16.427
Cash & Equivalents 55.329 56.349 47.913 32.712 16.427
Total Receivables, Net 18.367 5.281 2.784 3.656 3.774
Accounts Receivable - Trade, Net 18.367 5.281 2.784 3.656 3.774
Other Current Assets, Total 7.548 6.82 5.748 7.245 7.032
Total Assets 115.486 101.804 89.997 76.097 61.651
Property/Plant/Equipment, Total - Net 3.387 3.378 4.432 4.179 6.247
Property/Plant/Equipment, Total - Gross 10.369 10.471 11.827 10.928 13.409
Accumulated Depreciation, Total -6.982 -7.093 -7.395 -6.749 -7.162
Goodwill, Net 15.031 15.031 15.031 15.031 15.031
Intangibles, Net 12.821 12.4 11.992 11.617 11.131
Other Long Term Assets, Total 3.003 2.545 2.097 1.657 2.009
Total Current Liabilities 16.124 21.272 22.787 28.96 29.811
Accounts Payable 3.747 1.16 1.6 1.662 2.12
Accrued Expenses 2.622 2.959 3.533 4.899 4.597
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.707 3.106 0.02 0.019 0.051
Other Current Liabilities, Total 7.048 14.047 17.634 22.38 23.043
Total Liabilities 79.054 76.031 73.964 56.37 53.87
Total Long Term Debt 30.328 29.955 29.975 9.993 10.055
Long Term Debt 30.328 29.955 29.975 9.993 10.055
Other Liabilities, Total 32.602 24.804 21.202 17.417 14.004
Total Equity 36.432 25.773 16.033 19.727 7.781
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.027 0.027 0.027 0.031 0.032
Additional Paid-In Capital 302.18 302.923 304.697 321.669 325.308
Retained Earnings (Accumulated Deficit) -265.775 -277.177 -288.691 -301.973 -317.559
Total Liabilities & Shareholders’ Equity 115.486 101.804 89.997 76.097 61.651
Total Common Shares Outstanding 26.7854 26.9489 27.0201 30.7896 31.8893
  • Annual
  • Quarterly
2018 2019 2020 2021
Net income/Starting Line -26.166 -30.726 -31.35 -43.159
Cash From Operating Activities -17.677 -21.726 -21.366 -28.223
Cash From Operating Activities 1.74 2.793 2.903 3.178
Non-Cash Items 6.496 7.852 11.882 7.167
Changes in Working Capital 0.253 -1.645 -4.801 4.591
Cash From Investing Activities -0.617 -1.872 -2.927 -2.547
Capital Expenditures -0.617 -1.416 -2.177 -2.547
Other Investing Cash Flow Items, Total 0 -0.456 -0.75 0
Cash From Financing Activities 19.032 22.972 81.131 1.262
Financing Cash Flow Items -0.283 -0.119 -8.249 -0.5
Issuance (Retirement) of Stock, Net 8.55 10.047 73.34 17.112
Issuance (Retirement) of Debt, Net 10.765 13.044 16.04 -15.35
Net Change in Cash 0.738 -0.626 56.838 -29.508
Cash Interest Paid 1.844 1.676
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -6.961 -18.363 -29.877 -43.159 -15.586
Cash From Operating Activities -11.326 -10.236 -18.026 -28.223 -13.099
Cash From Operating Activities 0.746 1.523 2.323 3.178 0.908
Non-Cash Items 3.721 5.336 4.704 7.167 2.674
Changes in Working Capital -8.832 1.268 4.824 4.591 -1.095
Cash From Investing Activities -0.516 -0.864 -1.906 -2.547 -0.352
Capital Expenditures -0.516 -0.864 -1.906 -2.547 -0.352
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities 4.951 5.229 5.625 1.262 -2.834
Financing Cash Flow Items -0.108 -0.109 0.232 -0.5 -4.6
Issuance (Retirement) of Stock, Net 0.475 0.679 0.739 17.112 1.674
Issuance (Retirement) of Debt, Net 4.584 4.659 4.654 -15.35 0.092
Net Change in Cash -6.891 -5.871 -14.307 -29.508 -16.285
Cash Interest Paid 0.223
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Schuler (Jack W) Individual Investor 27.8328 19952112 8695652 2022-11-21 LOW
Kennedy (Lawrence T Jr.) Individual Investor 20.684 14827404 0 2023-01-03 MED
Patience (John) Individual Investor 9.7923 7019695 1739130 2022-11-21 LOW
Birchview Capital, LP Investment Advisor 7.0302 5039633 2884624 2022-12-31 LOW
Cawthorn (Robert E) Individual Investor 5.0948 3652220 1723341 2022-11-21 LOW
Strobeck (Matthew W) Individual Investor 4.052 2904668 1304345 2022-11-21 LOW
Industrial Development Funding LLC Corporation 2.6454 1896374 0 2022-03-01 LOW
Wells Fargo Advisors Research Firm 1.0724 768725 221413 2022-09-30 LOW
Essex Investment Management Company, LLC Investment Advisor/Hedge Fund 0.5273 377994 -29 2022-12-31 LOW
Life Sciences Alternative Financing, L.L.C. Corporation 0.4102 294053 0 2022-03-01 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.3343 239656 59660 2022-09-30 LOW
Cannell & Co. Investment Advisor 0.2868 205605 0 2022-12-31 LOW
Hutton Scott Individual Investor 0.2389 171227 96218 2022-11-21 LOW
Massarany (Hany) Individual Investor 0.1924 137934 130434 2022-11-21 HIGH
Endurant Capital Management LP Hedge Fund 0.1815 130136 -617 2022-09-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.1731 124070 27282 2022-09-30 LOW
Millennium Management LLC Hedge Fund 0.1647 118048 728 2022-09-30 HIGH
Bridgeway Capital Management, LLC Investment Advisor 0.1395 100000 50000 2022-09-30 LOW
Pestano (Gary Anthony) Individual Investor 0.1294 92732 3474 2022-11-10
Cowie (Robin Harper) Individual Investor 0.1282 91920 25383 2022-11-21 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Biodesix, Inc. Company profile

About Biodesix Inc

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).

Industry: Medical & Diagnostic Laboratories

Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US

Income Statement

  • Annual
  • Quarterly

News

Japanese Yen Outlook

Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields

Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.

14:36, 6 February 2023
S&P 500, FTSE 100

S&P 500 & DAX 40 Forecast for the Week Ahead

S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance

16:30, 3 February 2023
Global Currencies.

FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis

USD, GBP/USD, USD/JPY forecasts for the week ahead.

15:56, 3 February 2023
Governor of the Bank of England Andrew Bailey addresses the media during the Monetary Policy Report press conference at the Bank of England, in London, on February 2, 2023

GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes

Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.

15:37, 2 February 2023
Gold bars

Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data

Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing

11:48, 2 February 2023

People also watch

Oil - Crude

75.12 Price
+2.340% 1D Chg, %
Long position overnight fee -0.0242%
Short position overnight fee 0.0085%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

2.51 Price
+4.110% 1D Chg, %
Long position overnight fee -0.1169%
Short position overnight fee 0.0827%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

22,911.60 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

12,484.40 Price
-0.640% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0076%
Overnight fee time 22:00 (UTC)
Spread 1.8

Market analysis

Silver coins and bullion

Silver price forecast for 2023 and beyond: Will the precious metal hang on to its recent gains?

16:02, 6 February 2023
Rendering of physical bitcoin tokens on black background

Bitcoin price prediction 2030-2050: Can BTC reach $1m?

15:05, 6 February 2023
A set of euro notes and dollar bills arranged geometrically

EUR/USD forecast: Will the euro rise continue?

13:25, 6 February 2023

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading